The Company's preclinical pipeline includes development of an oral product candidate for treatment of ABSSSI (Acute Bacterial Skin and Skin Structure Infections), upon which a development program ...

The Company's preclinical pipeline includes development of an oral product candidate for treatment of ABSSSI (Acute Bacterial Skin and Skin Structure Infections), upon which a ...

There's more, I think competition in the other indications, ABSSSI and CABP ... But there are other markets like for example Japan, which by that time we believe could be quite a meaningful ...

To take a trivial example, which of us ever undertakes laborious physical exercise, except to obtain some advantage from it? But who has any right to find fault with a man who chooses to enjoy a ...

The global acute bacterial skin and skin structure infections (ABSSSI) treatment market was valued at $7.27 billion in 2018 and is projected to reach $25.90 billion by 2032, with a CAGR of 9.5%.

Community-acquired ABSSSI), By Route of Administration (Oral, Parenteral), By Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy) and Regional Forecast 2019-2032. Discover What ...

Director of National Intelligence Tulsi Gabbard lists several 'recent examples of unauthorized leaks within the' intelligence ...

John Kounios is a professor of psychological and brain sciences at Drexel University. He is co-author of The Eureka Factor: ...

First ever head-to-head comparison of gut microbiome changes associated with ibezapolstat (IBZ) to other anti-CDI antibiotics in a germ-free mouse model Changes in alpha and beta microbiome ...

The Company's preclinical pipeline includes development of an oral product candidate for treatment of ABSSSI (Acute Bacterial Skin and Skin Structure Infections), upon which a development program ...

The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic ...